BioCentury
ARTICLE | Strategy

Greasing the public-private interface

How partners Bristol-Myers, Duke expect to speed up drug development

March 12, 2012 7:00 AM UTC

Bristol-Myers Squibb Co. and Duke University think their new partnership could be a model for other pharmas and universities to help speed all stages of drug development from preclinical research to post-marketing community outreach.

BMS and the Duke Translational Medicine Institute (DTMI) have formed a joint steering committee that includes scientists and operating managers of divisions like clinical operations and pharmacovigilance who will aim to find common areas of interest that could provide opportunities for collaboration...